CAR-NK cell therapy for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new treatment using engineered immune cells (CAR-NK cells) that target two markers found on glioblastoma tumors. The treatment is given directly into the brain to fight tumors that have come back after standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have glioblastoma or a high-grade glioma that has come back or gotten worse after standard treatment.
- You are scheduled for surgery or a biopsy to test your tumor for specific markers, or you have stored tumor tissue available.
- Your tumor must show at least two of these markers: IL13Rα2, EGFR (or its variant EGFRvIII), or B7-H3.
- You must be in generally good health (able to take care of yourself, score 60 or higher on a standard scale).
- You are willing to use birth control if you or your partner can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy called CAR-NK cells to treat glioblastoma or high-grade glioma that has come back or gotten worse after standard treatment. The cells are engineered to recognize and attack tumor cells in the brain.
This trial tests engineered immune cells (called NK cells) that are designed to fight glioblastoma, a deadly brain cancer. The cells are injected directly into the tumor and may help patients whose cancer has come back after standard treatment.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests a new treatment using your own immune cells that are genetically modified to find and attack brain tumor cells. It is for people with a type of brain cancer that has come back after standard therapy.
This early-phase study tests a combination of cells injected directly into the brain and an IV antibody to treat recurrent HER2-positive glioblastoma (or a related tumor, gliosarcoma). It may help by attacking the tumor locally in the brain while the antibody boosts the immune system’s response.
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two proteins often found on ovarian cancer cells. It is for people whose cancer has come back after at least two prior treatments.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.